The current screening method to diagnose prostate cancer is based on a measurement of serum prostate specific antigen (PSA) levels and a digital rectal examination, while the decisive diagnosis is based on the results of transrectal, ultrasound-guided prostate biopsies [6-8]. Here, KLK3 is linked to prostate carcinoma.